title: Which therapeutic strategy will achieve a cure for HIV-1?
abstract: Strategies to achieve a cure for HIV-1 infection can be broadly classified into three categories: eradication cure (elimination of all viral reservoirs), functional cure (immune control without reservoir eradication), or a hybrid cure (reservoir reduction with improved immune control). The many HIV-1 cure strategies being investigated include modification of host cells to resist HIV-1, engineered T cells to eliminate HIV-infected cells, broadly HIV-1 neutralizing monoclonal antibodies, and therapeutic vaccination, but the 'kick and kill' strategy to expose latent HIV-1 with latency reversing agents (LRAs) and kill the exposed cells through immune effector functions is currently the most actively pursued. It is unknown, however, whether LRAs can deplete viral reservoirs in vivo or whether current LRAs are sufficiently safe for clinical use.
authors.affiliation: Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Cillo
authors.affiliation: Division of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: jwm1@pitt.edu.
authors.forename: John W
authors.initials: JW
authors.lastname: Mellors
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D014775:Virus Activation / Q000187:drug effects; D017735:Virus Latency / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal